Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.
Level 5 - mechanism / opinion, no new human data
Narrative review of endocrine mechanisms without original human data or systematic review methodology.
PubMed 23657561 · doi:10.1007/s11154-013-9245-9
What was done
Narrative review describing the pathophysiology of the GHRH-GH-IGF1 axis in HIV, HAART, and AIDS from literature synthesis.
What was found
The abstract reports no quantitative data or statistical metrics. It details two distinct pathophysiological mechanisms: HIV lipodystrophy involves suppressed pituitary GH production driven by increased somatostatin tone, decreased ghrelin, increased free fatty acids, and insulin resistance; in contrast, AIDS wasting syndrome features elevated GH and low IGF-1 levels indicating GH resistance. Tesamorelin is noted as the FDA-approved GHRH analog for excess abdominal fat reduction in HIV lipodystrophy.
Why it matters
This paper delineates the contrasting endocrine mechanisms underlying lipodystrophy and wasting in HIV, providing the physiological rationale for targeted GHRH analog therapy.
Limits
As a narrative review, it reports no primary clinical data, quantitative effect sizes, or systematic search methodology. Long-term risk-benefit trials for tesamorelin were noted as lacking.
Cited by
- supports Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue that stimulates the pituitary to secrete growth hormone, which causes the liver to release IGF-1.